Literature DB >> 8429340

Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging.

J D Kelly1, A M Forster, B Higley, C M Archer, F S Booker, L R Canning, K W Chiu, B Edwards, H K Gill, M McPartlin.   

Abstract

A new cationic complex, [99mTc(tetrofosmin)2O2]+, where tetrofosmin is the ether functionalized diphosphine ligand 1,2-bis[bis(2-ethoxyethyl)phosphino]ethane, has been synthesized and evaluated for potential use in myocardial perfusion imaging. The structure of the complex has been determined by x-ray crystallography of the 99Tc analog. In comparison with previously reported 99mTc complexes of alkyl-phosphines, the tetrofosmin species shows substantially increased clearance from nontarget tissue, especially blood and liver. A freeze-dried kit formulation has been developed. The kit provides a product of high radiochemical purity up to 8 hr after reconstitution at room temperature.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429340

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  48 in total

Review 1.  Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues.

Authors:  P Kailasnath; A J Sinusas
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

2.  Application of pixel truncation to reduce intensity artifacts in myocardial SPECT imaging with Tc-99m tetrofosmin.

Authors:  Masao Funahashi; Tsuyoshi Shimonagata; Kazuhiro Mihara; Kazuyuki Kashiyama; Ryuichi Shimizu; Shuzo Machida; Kazuyuki Izumi; Hideo Kusuoka; Tsunehiko Nishimura; Noritake Hoki; Sei-Ichi Kawamoto
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

3.  Improved diagnostic accuracy of planar imaging with technetium 99m-labeled tetrofosmin compared with thallium-201 for the detection of coronary artery disease.

Authors:  R S Khattar; R C Hendel; J C Crawley; F J Wackers; P Rigo; B L Zaret; B S Sridhara; A Lahiri
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

4.  Myocardial ischemia in Kawasaki disease: evaluation with dipyridamole stress technetium 99m tetrofosmin scintigraphy.

Authors:  Tsuyoshi Fukuda; Masatoshi Ishibashi; Tatsuo Yokoyama; Masaki Otaki; Tohru Shinohara; Yoshihide Nakamura; Toshiharu Miyake; Takashi Kudoh; Hidetaka Oku
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

5.  Usefulness of technetium-99m tetrofosmin SPECT to detect abnormal myocardial perfusion in systemic lupus erythematosus or systemic sclerosis patients.

Authors:  H-B Hsu; C-H Kao
Journal:  Clin Rheumatol       Date:  2003-10-14       Impact factor: 2.980

Review 6.  Myocardial perfusion imaging agents: SPECT and PET.

Authors:  George A Beller; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

7.  Stress protocols and tracers.

Authors:  Milena J Henzlova; Manuel D Cerqueira; John J Mahmarian; Siu-Sun Yao
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

8.  Assessment of area at risk and efficacy of treatment in patients with acute coronary syndrome using 99mTc tetrofosmin imaging in humans.

Authors:  H Matsuo; S Watanabe; Y Nishida; T Matsubara; M Kano; A Sugiyama; Y Matsuno; H Oda; Y Kotoo; H Oohashi
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

9.  Technetium-99m tetrofosmin uptake in lung cancer: comparison with thallium-201.

Authors:  I Matsunari; S Kinuya; T Nishikawa; M Matoba; K Murakita; M Ohguchi; K Ichiyanagi; J Taki; N Tonami; K Hisada
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

10.  Enhanced detection of reversible myocardial hypoperfusion by technetium 99m-tetrofosmin imaging and first-pass radionuclide angiography after nitroglycerin administration.

Authors:  A Peix; A López; F Ponce; J Morales; A R de la Vega; C S Chesa; A M Maltas; D García-Barreto
Journal:  J Nucl Cardiol       Date:  1998 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.